Limbic Encephalitis Manifesting as Selective Amnesia and Seizure-like Activity: A Case Report

So-Yeon Kim¹, Yoo Hyun Um¹, Sung Chul Lim², Jong-Hyun Jeong¹
Departments of ¹Psychiatry and ²Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea

Limbic encephalitis (LE) is characterized by short-term memory loss, disorientation, agitation, seizures, and histopathological evidence of medial temporal lobe inflammation. Leucine-rich, glioma inactivated 1 (LGI-1) is an auto-antigen associated with LE. We report a 37-year-old male patient with LGI-1-related LE who presented with recurrent episodes of selective amnesia, seizure-like activity, confusion, and personality change. His symptoms were significantly improved with steroid therapy. Thorough differential diagnosis with consideration for autoimmune encephalitis should be in patients with presentation of symptoms, such as memory impairment, personality change and seizure-like activity, especially when other neurological diagnoses are excluded.

KEY WORDS: Anti-LGI-1 antibody encephalitis; Neuropsychiatric symptoms; Steroid therapy.

INTRODUCTION

Encephalitis is an acute inflammation in the brain that is characterized by presentation of diffuse or focal presentation of neuropsychiatric symptoms. Accurate diagnosis and adequate care are very important for preventing mortality in encephalitis. Incipient pathological changes of encephalitis commonly occur in limbic systems, and can cause neuropsychiatric symptoms including memory impairment, seizure, hallucination, personality change, sleep disturbance and disorientation. Moreover, mental status change and motor disturbances are also caused by encephalitis. If infectious, toxic and metabolic causes of encephalitis have been ruled out, autoimmune causes should be assessed.

In the absence of appropriate diagnosis and care, autoimmune encephalitis (AE) can be fatal or can result in irreversible cognitive impairment, progressive seizure and other various adverse effects. Therefore, early diagnosis and intervention in autoimmune limbic encephalitis (LE) is critical. AE is caused by auto-antibodies for synaptic proteins including N-methyl-D-aspartate (NMDA) receptor, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor and gamma-aminobutyric acid B (GABA_B) receptor. Especially, the voltage gated potassium channel (VGKC) is the main target of LE related antibodies. Two VGKC antibodies target binding sites, namely anti leucine-rich, glioma inactivated-1 (LGI-1) and anti-contactin-associated protein 2 (CASPR2).

Patients with anti-LGI-1 antibody AE present with typical symptoms including memory impairment, confusion and seizure. Moreover, fluid-attenuated inversion recovery (FLAIR) brain magnetic resonance imaging (MRI) shows increased signal intensity in medial temporal lobe, a pathognomonic sign of LE.

In this case, the patient initially showed selective amnesia and seizure-like movement, but there were no abnormal laboratory and electroencephalogram (EEG) findings. The patient’s symptoms improved after immunosuppressive therapy, but two independent tests conducted for the detection of anti-LGI-1 antibody reactivity yielded contrasting results.
CASE

A 37-year-old male patient visited our clinic for selective amnesia and seizure-like movement after sudden headache. Although there were no specific abnormal findings in blood chemistry and EEG, the patient kept complaining about experiencing intermittent sensations of the flow of an electric current. He also experienced seizure-like shivering and repeatedly asked for attention. His amnesia was progressively exacerbated. The patient was hospitalized on April 2015.

Three days after hospitalization, T2 weighted non-enhanced brain MRI showed high signal intensity in the medial temporal lobe and hippocampus (Fig. 1). Therefore, assessment of post-ictal signal changes and encephalitis was considered necessary. Examination of cerebrospinal fluid (CSF) and video EEG monitoring did not detect abnormalities. Conversion disorder was diagnosed and escitalopram 10 mg/day and clonazepam 0.5 mg/day were prescribed. In the initial interview, the patient displayed seizure-like movement in both arms and legs, and the interview was disrupted due to his selective amnesia. Although confusion and anxiety due to memory loss remained, the seizure-like movement gradually improved. Moreover, behavioral disturbances such as seizure like shivering and repetitive asking disappeared. Thus, the patient left hospital after 25 days.

Unfortunately, his problematic behaviors relapsed after discharge from the hospital. The patient performed repeated illegal behaviors including burglary, theft and a hit-and-run car accident. He did not recall some of the incidents. Moreover, he exhibited grandiose and violent behaviors, and was verbally abusive. Aripiprazole 30 mg/day or olanzapine 20 mg/day with valproic acid 500 mg/day were prescribed in the outpatient clinic but his symptoms did not improve. Therefore, the patient was

Fig. 1. Axial brain images of the patient. T2-weighted image show increased signal intensity in both medial temporal lobes and hippocampi at the first admission (A and B).

Fig. 2. Axial brain images of the patient. T2WI images demonstrated atrophy in both medial temporal lobes and hippocampi at the second admission (A and B).
Table 1. A brief history of this case

| Follow-up day | Clinical manifestation | Evaluation | Results |
|---------------|------------------------|------------|---------|
| Day 3         | Selective amnesia, headache, seizure-like activity | Brain MRI | T2W high signal intensities in both medial temporal lobes, hippocampi |
| Day 7         | Seizure-like activity (jerky movement), recent memory impairment | Brain SPECT, 24 hrs video EEG, CSF study | WNL, WNL |
| Day 25 (discharge) | Conversion disorder c attacks or seizures (diagnosis) | CSF study | WNL |
| Day 208 (2nd admission) | Selective amnesia, poor impulse control, incoherence, hyperactivity | Brain MRI | Atrophy in both medial temporal lobes, hippocampi |
| Day 210       | Selective amnesia, poor impulse control | Blood chemistry, CSF study | Hyponatremia (131.9 mEq/L) |
| Day 217       | GTC type seizure (45 sec) | 24 hrs video EEG, Blood chemistry | Sharp wave, left temporal lobe, Aggravated hyponatremia (122 mEq/L) |
| Day 230       | Anti-LGI-1 limbic encephalitis (diagnosis) | Autoimmune antibody study (CSF and serum) | Anti-LGI-1 antibody (+) |

MRI, magnetic resonance imaging; SPECT, single photon emission computed tomography; WNL, within normal limit; EEG, electroencephalogram; CSF, cerebrospinal fluid; GTC, generalized tonic-clonic; LGI-1, leucine-rich glioma inactivated-1.

re-admitted 208 days after discharge from his first admission, for more meticulous evaluation and symptom management.

During his second hospitalization, there were no signs of seizure-like movement, but selective amnesia and behavioral problems remained. Previous high signal intensity disappeared in a follow-up brain MRI, but bilateral hippocampal atrophy was detected (Fig. 2). On the ninth day of hospitalization, a generalized tonic-chronic seizure was observed for 45 seconds. Convulsive movement was not observed, but a sharp wave in the left temporal lobe was detected in video EEG monitoring. Nephrologists considered a possibility the syndrome of inappropriate secretion of anti-diuretic hormone (SIADH), since the initial sodium level was 131.9 mEq/L. Blood sodium levels gradually improved to normal sodium concentration range with 7.5 mg/day of the vasopressin 2 receptor antagonist, tolvaptan. The autoimmune studies in CSF and serum showed anti-LGI-1 positive reactivity. Classic paraneoplastic syndrome antibodies, such as anti-neuronal nuclear antibody 1 (anti-Hu), anti-Purkinje cell cytoplasmic antibody (anti-Yo), anti-neuronal nuclear antibody 2 (anti-Ri), anti-collapsing response mediator protein 5 antibody (anti-CV2/CRMP5) and anti-ampiphysin antibody were not detected. Moreover, autoimmune synaptic encephalitis antibodies including anti-NMDA, anti-AMPA1, anti-AMPA2, anti-CASPR2, and anti-GABA	extsubscript{B} were not evident.

The patient was prescribed with oxcarbazepine 1,500 mg/day, lorazepam 0.5 mg/day, and clonazepam 0.5 mg/day. Selective memory loss, generalized tonic-chronic seizure and behavioral problems improved, and he was discharged on day 25 following admission. The patient was referred to a neurological department for immunosuppressive therapy and upon the initiation treatment, and the patient was reassessed for anti-LGI-1 in CSF and serum. Although the result was anti-LGI-1 negative, the patient was treated with immunosuppressive therapy and was stabilized quickly. Table 1 chronicles the case. This case report was approved by the International Review Board of St. Vincent’s Hospital, The Catholic University of Korea (VC16ZISE0033).

**DISCUSSION**

The patient showed selective amnesia and seizure-like movement without any infections or inflammations in the CSF examination and no epileptic form in EEG monitoring. The patient was speculated to have conversion disorder, but seizure-like movement did not improved by anti-depressant and anxiolytics treatment. Moreover, atypical anti-psychotics and anxiolytics treatment for symptoms, such as confusion or illegal behavior, were also useless. Medial temporal lobe atrophy in brain MRI and left medial temporal lobe epilepsy in video EEG monitoring were detected. SIADH was sus-
pected due to decreased sodium levels (122 mEq/L), and blood sodium levels were improved by tolvaptan treatment. Interestingly, the symptoms improved after immunosuppressive therapy. Although the initial autoimmune studies showed positive anti-LGI-1 reactivity, reassessment before immunotherapy showed negative anti-LGI-1 reactivity.

Sero-negative limbic encephalitis had been reported, but our case cannot be explained by the aforementioned diagnosis due to one positive result for anti-LGI-1. A possible explanation for this phenomenon is change of antibody titer. Antibody disappearance in blood and decreased antibody titer in CSF were reported in case of anti-NMDA receptor encephalitis. Symptoms of encephalitis might have fluctuated in accordance with anti-NMDA receptor antibody titer. Patient with sustained symptoms due to delayed diagnosis or immunotherapy can present with anti-NMDA receptor Ab positive results only in CSF and symptoms were improved with decreased Ab titer.

Our case showing contrary anti-LGI-1 reactivity, initial positive and subsequent negative results may be explained by the aforementioned case.

LGI-1 is a single human epilepsy-related gene encoding secreted neuronal protein. LGI-1 mutation is related to autosomal dominant lateral temporal lobe epilepsy. This genetic syndrome causes hallucinations and partial seizures, but the incidence rate is very low. The main role of LGI-1 in epilepsy is memory impairment and seizure. The expression of LGI-1 was reported even in kidney, and about 60% of anti-LGI-1 Ab AE present with severe hyponatremia. In Thailand, prospective study of 103 AE patients showed behavioral symptoms including psychosis (6/25 patients) and seizures (6/25 patients). Nevertheless, high suspicion for anti-LGI-1 Ab AE can be overlooked in patients with behavioral symptoms. Therefore, Initial diagnosis can be confusing and can result in a delayed diagnosis of autoimmune LE. The therapeutic protocols for anti-LGI-1 antibody AE are not yet established. Recently, the effectiveness of steroid therapy in recurrent memory disorder by anti-LGI-1 antibody AE was described. Moreover, immunosuppressive therapy can be more effective in cell surface antibodies including anti-NMDA, anti-LGI-1, anti-CASPR-2, anti-AMPA and anti-GABAB receptors than cellular antigens, which are classic paraneoplastic syndrome antibodies.

Three possible molecular functions of LGI-1 have been proposed. LGI-1 prevents the inactivation of the Kv1 VGKC through the cytoplasmic regulatory protein Kvβ. LGI-1 regulates the neuronal development of glutamatergic circuits in the hippocampus. Finally, LGI-1 interacts with the epilepsy-related AD-AM22/23 transmembrane proteins and regulates AMPA receptor-mediated synaptic transmission in the hippocampus. Recently, there have been reports of LGI-1 autoantibodies specifically causing LE through inhibiting the ligand-receptor interaction between LGI-1 and AD-AM22 that controls AMPA receptor functions. Nevertheless, the potential molecular mechanism of Anti-LGI-1 antibody AE is not yet been fully understood.

In conclusion, this case suggests differential diagnosis of AE should be conducted in a patient with atypical presentation of neuropsychiatric symptoms, such as memory impairment, personality change and seizure-like activity (with thorough review of medications that might have induced seizures), especially when other neurological diagnoses have been excluded.

REFERENCES

1. Wingfield T, McHugh C, Vas A, Richardson A, Wilkins E, Bonington A, et al. Autoimmune encephalitis: a case series and comprehensive review of the literature. QJM 2011;104:921-931.
2. Thieben M, Lennon VA, Boeve BF, Aksamit A, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004;62:1177-1182.
3. Han SW, Joo JJ, Kang JH, Ha SW, Yang YS. Non-paraneoplastic autoantibody-negative limbic encephalitis characterized by mild memory impairment: a case report. Dement Neurocognitive Disord 2014;13:79-82.
4. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detett N, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127:701-712.
5. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9:776-783.
6. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011;77:179-189.
7. Ahmad SB, Archer HA, Rice CM, Gerhard S, Bradley M, Wilkins A. Seronegative limbic encephalitis: case report, literature review and proposed treatment algorithm. Pract Neurol 2011;11:355-361.
Limbic Encephalitis Manifesting as Selective Amnesia and Seizure-like Activity

9. Gu W, Brodtkorh E, Steinlein OK. LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann Neurol 2002;52:364-367.

10. Senechal KR, Thaller C, Noebels JL. ADPEAF mutations reduce levels of secreted LGI1, a putative tumor suppressor protein linked to epilepsy. Hum Mol Genet 2005;14:1613-1620.

11. Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012;72:241-255.

12. McQuillan RF, Bargman JM. Hyponatraemia caused by LGI1-associated limbic encephalitis. NDT Plus 2011;4:424-426.

13. Saraya A, Mahavihakanont A, Shuangshoti S, Sittidethoripat N, Deesundhit T, Callahan M, et al. Autoimmune causes of encephalitis syndrome in Thailand: prospective study of 103 patients. BMC Neurol 2013;13:150.

14. Noh KH, Kim SJ, Cho JW, Shin JH, Lee JH. Steroid responsive recurrent limbic encephalitis associated with LGI1 antibodies. J Korean Neurol Assoc 2014;32:91-94.

15. Schulte U, Thumfart JO, Klöcker N, Sailer CA, Bildl W, Biniossek M, et al. The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvbeta1. Neuron 2006;49:697-706.

16. Zhou YD, Lee S, Jin Z, Wright M, Smith SE, Anderson MP. Arrested maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. Nat Med 2009;15:1208-1214.

17. Fukata Y, Lovero KL, Iwanaga T, Watanabe A, Yokoi N, Tabuchi K, et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci U S A 2010;107:3799-3804.

18. Ohkawa T, Fukata Y, Yamasaki M, Miyazaki T, Yokoi N, Takashima H, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013;33:18161-18174.

19. Bolu A, Akarsu S, Pan E, Aydemir E, Ozdur T. Low-dose clonazepam-induced seizure: A case report. Clin Psychopharmacol Neurosci 2017;15:190-193.

20. Itil TM, Soldatos C. Epileptogenic side effects of psychotropic drugs. Practical recommendations. JAMA 1980;244:1460-1463.